Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibators, lra drugs, anti-h1 and/or anti-h2 drugs

Abstract

The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.

1 . A method for the treatment of gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor. 
     
     
         2 . The method of  claim 1 , further comprising administering to the subject an effective amount of an anti-H1 drug. 
     
     
         3 . The method of  claim 1 , further comprising administering to the subject an effective amount an anti-H2 drug. 
     
     
         4 . The method of  claim 1 , further comprising administering to the subject an effective amount of an anti-H1 drug and an anti-H2 drug. 
     
     
         5 .- 8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the gastrointestinal disease condition is selected from a group consisting of GERD, a food allergy, Zollinger-Ellison Syndrome, peptic ulcer, dyspepsia, allergic eosinophilic gastroenteritis, and mastocytosis with gastrointestinal symptoms. 
     
     
         10 . The method of  claim 1 , wherein the histidine decarboxylase inhibitor is selected from a group consisting of Tritoqualine or an isomer thereof, alpha-fluoromethylhistidine, 3-methoxy-5,7,3,4′-tetrahydroxyflavan, naringenin, (+)-cyanidanol-3, the dipeptide His-Phe, 4-imidazolyl-3-amino-2-butanone, epigallocatechin gallate and other catechin based inhibitors of HDC. 
     
     
         11 . The method of  claim 1 , wherein the histidine decarboxylase inhibitor is Tritoqualine and the effective amount of Tritoqualine is 200 mg/day. 
     
     
         12 . The method of  claim 2 , wherein the anti-H1 chug is selected from a group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxizine, ketotifen, loratadine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochloride, doxylamine, mepyramine, antazoline, diphenhydramine, carbinoxamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine, triprolidine, chlorcyclizine, hydroxyzine, meclizine, promethazine, and azatadine. 
     
     
         13 .- 14 . (canceled) 
     
     
         15 . The method of  claim 12 , wherein the anti-H1 drug is fexofenidine and the effective amount of fexofenidine is 120.0 mg/day. 
     
     
         16 . The method of  claim 3 , wherein the anti-H2 drug is selected from a group consisting of ranitidine, cimetidine, famotidine, and nizatidine. 
     
     
         17 . The method of  claim 16 , wherein the anti-H2 drug is ranitidine and the effective amount of ranitidine is 150 mg/day. 
     
     
         18 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         19 . The method of  claim 18 , wherein the mammal is any of a human, monkey, ape, dog, cat, cow, horse, rabbit, mouse, or rat. 
     
     
         20 . The method of  claim 1 , wherein the administration is effected locally or systemically. 
     
     
         21 . (canceled) 
     
     
         22 . A method for the treatment of food allergy in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor. 
     
     
         23 . The method of  claim 22 , further comprising administering to the subject an effective amount of an anti-H1 drug. 
     
     
         24 . The method of  claim 22 , further comprising administering to the subject an effective amount an anti-H2 drug. 
     
     
         25 . The method of  claim 22 , further comprising administering to the subject an effective amount of a LRA drug. 
     
     
         26 . The method of  claim 22 , further comprising administering to the subject an effective amount of a LRA drug, an anti-H1 drug, and an anti-H2 drug. 
     
     
         27 . A pharmaceutical formulation comprising a combination of:
 a. A Histadine decarboxylase inhibitor,   b. An anti-H1 drug,   c. an anti-H2 drug, and   d. a pharmaceutically acceptable carrier.